12 September 2018 13:30
Photo : Unsplash
According to the report CompassRx of the review Board the patented medicine prices (PMPRB), the costs of publicly-funded drug plans have increased by 1.9 % in 2016-2017, up to a total of 10.7 billion dollars (G$). The growth in 2015-2016, however, was significantly higher at 10.8 %.
The study included the public insurance plans, the following drugs of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward island, Newfoundland and Labrador, and of Program non-insured health benefits from Health Canada.
Increased use of drugs more expensive
According to the PMPRB, the increase in the cost of medicines in the public plans, in 2016-2017, is attributable to a greater use of drugs more costly, a reduction in savings of generic drugs and a decrease of the antiviral drugs with a direct action (ADF). The drugs that are more expensive (other than the ADF), continue to be the most critical factor, resulting in an increase of the costs of 4.4% in 2016-2017. “
The study revealed that the drugs whose annual cost of treatment was above $ 10,000 increased by 17.2 %. “These drugs at high costs, were used by less than 2 % of the beneficiaries of public insurance plans, drugs and accounted for nearly 28 % of the total cost of drugs in 2016 and 2017. “
Substitutions generics and biosimilars
The cost savings linked to price reductions and substitutions of generics and biosimilars have steadily decreased, from -9,2% in 2012/13 to 2.8% in 2016/17, after the reduction of the impact of the reforms of the patents and the price of the generic, the report said.